THE SUCCESSFUL APPLICATION OF A DOCETAXEL AND MITOTANE THERAPEUTIC COMBINATION IN THE FOURTH LINE TREATMENT OF ADVANCED ADRENOCORTICAL CARCINOMA: A CASE REPORT

Adrenocortical carcinoma (ACC) is a rare aggressive tumor of the adrenal cortex with high malignant potential.
ACC is characterized by frequent relapses after surgical treatment, resistance to local and systemic therapy in advanced
disease and poor prognosis. At present, a combination of a steroidogenesis inhibitor mitotane and chemotherapeutic
agents of etoposide, doxorubicin and cisplatin is used for treatment of metastatic ACC. A combination of mitotane,
gemcitabine and capecitabine can be used in pretreated ACC patients. However, it is unclear which chemotherapy
regimens are administered in the second and subsequent treatment lines of advanced ACС. This case report is devoted
to the successful application of a combination of docetaxel and mitotane in a 30-year-old patient with metastatic
ACC after three previous chemotherapy regimens.